miR-379 appears to increase cholesterol lipotoxicity, leading to the development and progression of NAFLD, via interference with the expression of target genes, including those related to the IGF-1 signaling pathway. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.